In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
The following faculty have reported relationships with ineligible companies:
George L. Bakris, MD, faculty for this educational event, has received consulting fees from Bayer, KBP Biosciences, Ionis, Alnylam, Astra Zeneca, Quantum Genomics, Horizon, Novo Nordisk, Dia Medica Therapeutics, and InREGEN.
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA, faculty for this educational event, has received consulting fees from Amgen, Novartis, Medtronic, Eli Lilly, and Quantum Genomics.
Michael G. Nanna, MD, MHS, faculty for this educational event, has no relevant financial relationships with ineligible companies.
Sudarshan Rajagopal, MD, PhD, faculty for this educational event, received consulting fees from Altavant, Gossamer Bio, Insmed, Janssen, Liquidia, Polarean, and United Therapeutics; received research funding from Janssen, United Therapeutics, and Altavant; has ownership interest in Apie Therapeutics; receives royalties from Polarean; and is a patent holder with Polarean.
Nishant Shah, MD, FACC, faculty for this educational event, has received research funding from Amgen, Novartis, and Janssen; and has received consulting fees from Amgen, Novartis, and Esperion.
Sreekanth Vemulapalli, MD, faculty for this educational event, received consulting fees from American College of Physicians, Edwards Lifesciences, and Medtronic; received research funding from Cytokinetics, Abbott Vascular, Boston Scientific, American College of Cardiology, Society of Thoracic Surgeons.